Proof-of-concept Trial of Apraglutide in GVHD

Active:	No
Cancer Type:	Unknown Primary	NCT ID:	NCT05415410
Trial Phases:	Phase II	Protocol IDs:	TA799-101 (primary) NCI-2022-05062
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	VectivBio AG
NCI Full Details:	http://clinicaltrials.gov/show/NCT05415410

Summary

The aim of this trial is to assess safety and efficacy of apraglutide in subjects with
steroid refractory gastrointestinal acute graft versus host disease (aGVHD).

Objectives

This is an international, multicenter, randomized proof-of-concept trial to evaluate
safety, tolerability, efficacy, durability of response, and clinical outcomes of
apraglutide administration to subjects with steroid-refractory (SR) aGVHD of the lower GI
tract being treated with systemic steroids (SS) and ruxolitinib (RUX).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.